Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Beyond the dose: social determinants and treatment intensity in DLBCL.
Journal: Leukemia & lymphoma
Published: June 15, 2026
HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Treatment-Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions.
Journal: European journal of haematology
Published: January 19, 2026
Prognostic value of patient-reported outcome thresholds on survival and adverse events in CLL/SLL: A pooled analysis of ibrutinib trials.
Journal: Therapeutic advances in hematology
Published: November 24, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.
Journal: Frontiers in oncology
Published: July 11, 2025
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.
Journal: European journal of haematology
Published: January 17, 2025
LOAd703 and chemotherapy combination in pancreatic cancer: insights from the LOKON001 study.
Journal: Translational gastroenterology and hepatology
Published: October 20, 2024
Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
Journal: Therapeutic advances in medical oncology
Published: March 25, 2024
Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.
Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.
Journal: American journal of therapeutics
Published: September 15, 2023
Last Updated: 09/26/2026